Therapeutic properties of DNA-based fibroblast and dendritic cell vaccines in mice with squamous carcinoma

Insug O-Sullivan, Tae Sung Kim, Amla Chopra, Edward P. Cohen

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Dendritic cells (DC) express class I/II MHC-determinants and co-stimulatory molecules required for T cell activation. In a mouse model of squamous cell carcinoma (SCC), we compared the immunogenic properties of allogeneic DNA-based fibroblast vaccines, which are taken up and processed by DC of the host, and syngeneic DNA-based DC vaccines, which present antigens directly. The incentive was the important practical advantages of using fibroblasts rather than DC in generating vaccines for the immunotherapy of SCC. Materials and Methods: The fibroblast vaccine was prepared by transfer of genomic DNA-fragments (25 kb) from relatively small numbers (107=64 mm3 tumor) of SCCVII/SF cells into LM cells, a mouse fibroblast cell line (H-2k). SCCVII/SF cells are a highly aggressive squamous carcinoma cell line of C3H/He mouse origin (H-2k). As the transferred DNA spontaneously integrates into the genome of the recipient cells, and is replicated as the cells divide, the number of transfected fibroblasts could be conveniently expanded for repeated immunizations. Syngeneic DC, rather than fibroblasts, were also used as the recipients of DNA from the SCC. C3H/He mice, highly susceptible to growth of SCCVII/SF cells, were immunized with either the DNA- based fibroblast or the DNA-based DC vaccine and the antitumor immune responses were compared. Results: Robust CD8+ T cell-mediated antitumor immunity sufficient to deter the growth of the neoplastic cells was generated in mice immunized with the transfected fibroblasts, but not in mice immunized with the transfected DC. Conclusion: These data raise the possibility that an analogous strategy could be used to treat squamous carcinoma patients with minimal residual disease after primary therapy.

Original languageEnglish
Pages (from-to)873-884
Number of pages12
JournalAnticancer Research
Volume26
Issue number2 A
Publication statusPublished - 2006 Mar 1

Fingerprint

Fibroblasts
Dendritic Cells
Squamous Cell Carcinoma
Vaccines
DNA
T-cells
Inbred C3H Mouse
Therapeutics
Cells
Immunization
T-Lymphocytes
Cell Line
Residual Neoplasm
Growth
Cellular Immunity
Immunotherapy
Motivation
Tumors
Cell Count
Genes

Keywords

  • Dendritic cells
  • DNA
  • Fibroblasts
  • Squamous carcinoma
  • Vaccine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Therapeutic properties of DNA-based fibroblast and dendritic cell vaccines in mice with squamous carcinoma. / O-Sullivan, Insug; Kim, Tae Sung; Chopra, Amla; Cohen, Edward P.

In: Anticancer Research, Vol. 26, No. 2 A, 01.03.2006, p. 873-884.

Research output: Contribution to journalArticle

O-Sullivan, Insug ; Kim, Tae Sung ; Chopra, Amla ; Cohen, Edward P. / Therapeutic properties of DNA-based fibroblast and dendritic cell vaccines in mice with squamous carcinoma. In: Anticancer Research. 2006 ; Vol. 26, No. 2 A. pp. 873-884.
@article{205b2b2e41be4e96a9f775f1daa754e7,
title = "Therapeutic properties of DNA-based fibroblast and dendritic cell vaccines in mice with squamous carcinoma",
abstract = "Background: Dendritic cells (DC) express class I/II MHC-determinants and co-stimulatory molecules required for T cell activation. In a mouse model of squamous cell carcinoma (SCC), we compared the immunogenic properties of allogeneic DNA-based fibroblast vaccines, which are taken up and processed by DC of the host, and syngeneic DNA-based DC vaccines, which present antigens directly. The incentive was the important practical advantages of using fibroblasts rather than DC in generating vaccines for the immunotherapy of SCC. Materials and Methods: The fibroblast vaccine was prepared by transfer of genomic DNA-fragments (25 kb) from relatively small numbers (107=64 mm3 tumor) of SCCVII/SF cells into LM cells, a mouse fibroblast cell line (H-2k). SCCVII/SF cells are a highly aggressive squamous carcinoma cell line of C3H/He mouse origin (H-2k). As the transferred DNA spontaneously integrates into the genome of the recipient cells, and is replicated as the cells divide, the number of transfected fibroblasts could be conveniently expanded for repeated immunizations. Syngeneic DC, rather than fibroblasts, were also used as the recipients of DNA from the SCC. C3H/He mice, highly susceptible to growth of SCCVII/SF cells, were immunized with either the DNA- based fibroblast or the DNA-based DC vaccine and the antitumor immune responses were compared. Results: Robust CD8+ T cell-mediated antitumor immunity sufficient to deter the growth of the neoplastic cells was generated in mice immunized with the transfected fibroblasts, but not in mice immunized with the transfected DC. Conclusion: These data raise the possibility that an analogous strategy could be used to treat squamous carcinoma patients with minimal residual disease after primary therapy.",
keywords = "Dendritic cells, DNA, Fibroblasts, Squamous carcinoma, Vaccine",
author = "Insug O-Sullivan and Kim, {Tae Sung} and Amla Chopra and Cohen, {Edward P.}",
year = "2006",
month = "3",
day = "1",
language = "English",
volume = "26",
pages = "873--884",
journal = "The BMJ",
issn = "0730-6512",
publisher = "Kluwer Academic Publishers",
number = "2 A",

}

TY - JOUR

T1 - Therapeutic properties of DNA-based fibroblast and dendritic cell vaccines in mice with squamous carcinoma

AU - O-Sullivan, Insug

AU - Kim, Tae Sung

AU - Chopra, Amla

AU - Cohen, Edward P.

PY - 2006/3/1

Y1 - 2006/3/1

N2 - Background: Dendritic cells (DC) express class I/II MHC-determinants and co-stimulatory molecules required for T cell activation. In a mouse model of squamous cell carcinoma (SCC), we compared the immunogenic properties of allogeneic DNA-based fibroblast vaccines, which are taken up and processed by DC of the host, and syngeneic DNA-based DC vaccines, which present antigens directly. The incentive was the important practical advantages of using fibroblasts rather than DC in generating vaccines for the immunotherapy of SCC. Materials and Methods: The fibroblast vaccine was prepared by transfer of genomic DNA-fragments (25 kb) from relatively small numbers (107=64 mm3 tumor) of SCCVII/SF cells into LM cells, a mouse fibroblast cell line (H-2k). SCCVII/SF cells are a highly aggressive squamous carcinoma cell line of C3H/He mouse origin (H-2k). As the transferred DNA spontaneously integrates into the genome of the recipient cells, and is replicated as the cells divide, the number of transfected fibroblasts could be conveniently expanded for repeated immunizations. Syngeneic DC, rather than fibroblasts, were also used as the recipients of DNA from the SCC. C3H/He mice, highly susceptible to growth of SCCVII/SF cells, were immunized with either the DNA- based fibroblast or the DNA-based DC vaccine and the antitumor immune responses were compared. Results: Robust CD8+ T cell-mediated antitumor immunity sufficient to deter the growth of the neoplastic cells was generated in mice immunized with the transfected fibroblasts, but not in mice immunized with the transfected DC. Conclusion: These data raise the possibility that an analogous strategy could be used to treat squamous carcinoma patients with minimal residual disease after primary therapy.

AB - Background: Dendritic cells (DC) express class I/II MHC-determinants and co-stimulatory molecules required for T cell activation. In a mouse model of squamous cell carcinoma (SCC), we compared the immunogenic properties of allogeneic DNA-based fibroblast vaccines, which are taken up and processed by DC of the host, and syngeneic DNA-based DC vaccines, which present antigens directly. The incentive was the important practical advantages of using fibroblasts rather than DC in generating vaccines for the immunotherapy of SCC. Materials and Methods: The fibroblast vaccine was prepared by transfer of genomic DNA-fragments (25 kb) from relatively small numbers (107=64 mm3 tumor) of SCCVII/SF cells into LM cells, a mouse fibroblast cell line (H-2k). SCCVII/SF cells are a highly aggressive squamous carcinoma cell line of C3H/He mouse origin (H-2k). As the transferred DNA spontaneously integrates into the genome of the recipient cells, and is replicated as the cells divide, the number of transfected fibroblasts could be conveniently expanded for repeated immunizations. Syngeneic DC, rather than fibroblasts, were also used as the recipients of DNA from the SCC. C3H/He mice, highly susceptible to growth of SCCVII/SF cells, were immunized with either the DNA- based fibroblast or the DNA-based DC vaccine and the antitumor immune responses were compared. Results: Robust CD8+ T cell-mediated antitumor immunity sufficient to deter the growth of the neoplastic cells was generated in mice immunized with the transfected fibroblasts, but not in mice immunized with the transfected DC. Conclusion: These data raise the possibility that an analogous strategy could be used to treat squamous carcinoma patients with minimal residual disease after primary therapy.

KW - Dendritic cells

KW - DNA

KW - Fibroblasts

KW - Squamous carcinoma

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=33645829513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645829513&partnerID=8YFLogxK

M3 - Article

C2 - 16619482

AN - SCOPUS:33645829513

VL - 26

SP - 873

EP - 884

JO - The BMJ

JF - The BMJ

SN - 0730-6512

IS - 2 A

ER -